XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

Laureate Pharma's protein purification and other production processes are pure poetry in motion. The contract manufacturing organization (CMO) develops, manufactures, and packages products used by pharmaceutical and biopharmaceutical companies to make drugs and diagnostics. The company's biopharmaceutical division specializes in making monoclonal antibodies and provides protein production and purification. Laureate also provides product formulation, aseptic filling, and bulk processing. It has partnerships with EMD Chemicals and GTC Biotherapeutics to provide products for clinical trials. Investment firm Safeguard Scientifics has sold its majority stake in Laureate Pharma to Saints Capital.

Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Peregrine Pharmaceuticals, Inc. company was founded in 1981 and is based in Tustin, California. Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies.

Arrow Therapeutics was founded in 1998; AstraZeneca acquired the firm in 2007. Arrow Therapeutics is a pharmaceutical product discovery company that is researching new anti-infective medicines. The company's top candidate is RSV604, an antiviral molecular program to combat respiratory syncytial virus (RSV), a leading cause of respiratory infections worldwide. This candidate is currently undergoing clinical trials and has been licensed to Novartis. Other leading programs include compounds developed to fight infectious dieseases such as Hepatitis C, herpes, and chicken pox.

Pathwork Diagnostics is hoping to offer doctors the ability to predict which diseases a patient may have. The company is developing methods to identify biomarker patterns that indicate certain types of diseases. Many tests cannot identify diseases in their early forms. Pathwork Diagnostics is working on identifying the earliest possible signs of a given disease, such as cancer, to help doctors determine the best therapies to treat that disease. The company was founded in 2002. Investment firms Advent Venture, Prospect Venture, and Versant Ventures are the largest shareholders.

AERES Biomedical Ltd. company was founded in 1999. AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.